Kayne Anderson Rudnick Investment Management
COLL icon

Kayne Anderson Rudnick Investment Management’s Collegium Pharmaceutical COLL Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-71
Closed -$1K – 618
2022
Q1 		$1K Buy
+71
New +$1.34K ﹤0.01% 624

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's COLL Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Collegium Pharmaceutical (COLL) in Q2 2022, closing a stake of 71 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in COLL in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 157 funds tracked by Wall St. Rank hold COLL as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Collegium Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 71 Collegium Pharmaceutical shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Collegium Pharmaceutical in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Collegium Pharmaceutical position peaked at $1K in Q1 2022.
  • 157 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.